BCM
ENGN icon

BML Capital Management’s enGene Therapeutics ENGN Stock Holding History

BML Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Buy
+6,669,908
New +$27.2M 6.55% 3

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BML Capital Management's ENGN Position: Q2 2026 in Review

BML Capital Management opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 6,669,908 shares worth $11.5M. The stake represents 6.55% of the portfolio and ranks #3 among its holdings.

60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • BML Capital Management held 6,669,908 shares of enGene Therapeutics worth $11.5M as of Q2 2026.
  • enGene Therapeutics was a new BML Capital Management position in Q2 2026.
  • enGene Therapeutics made up 6.55% of BML Capital Management's portfolio in Q2 2026, its #3 holding.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.